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Clinical study protocol for a low-
interventional study in intermediate age-
related macular degeneration developing
novel clinical endpoints for interventional
clinical trials with a regulatory and patient
access intention—MACUSTAR
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Gary S. Rubin3, Hannah Dunbar3, Adnan Tufail4, David P. Crabb5, Alison Binns5, Clara I. Sánchez6, Carel Hoyng6,
Philippe Margaron7, Nadia Zakaria7, Mary Durbin8, Ulrich Luhmann9, Parisa Zamiri7, José Cunha-Vaz10,
Cecília Martinho10, Sergio Leal11, Robert P. Finger1* and on behalf of the MACUSTAR consortium
Abstract
Background: There is an unmet need for treatment options in intermediate age-related macular degeneration
(iAMD). However, for any new interventions to be tested in clinical trials, novel currently unavailable clinical
endpoints need to be developed. Thus, the MACUSTAR study aims to develop and evaluate functional, structural,
and patient-reported candidate endpoints for use in future iAMD trials.
Methods: The protocol describes a low-interventional clinical multicenter study employing a novel two-part design.
The cross-sectional part (total duration, 1 month) and the longitudinal part (total duration, 36 months) include
participants with iAMD and control groups with early/late/no AMD. The cross-sectional part’s primary objective is a
technical evaluation of functional, structural, and patient-reported candidate outcomes. The longitudinal part’s
primary objective is to assess the prognostic power of changes in functional, structural, and patient-reported
outcomes for progression from iAMD to late AMD. All data will be used to support a biomarker qualification
procedure by regulatory authorities.
Discussion: The MACUSTAR study characterizes and evaluates much needed novel functional, structural, and
patient-reported endpoints for future clinical trials in iAMD and will improve our understanding of the natural
history and prognostic markers of this condition.
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Background
Age-related macular degeneration (AMD) is one of the
main causes of irreversible severe visual loss in high-
income countries, characterized by typical morphologic
and functional changes of the central outer retina [1, 2].
The disease progresses slowly from early and intermedi-
ate AMD (iAMD) with drusen as a key finding, possible
retinal pigmentary changes and none to moderate visual
symptoms to late AMD with damage of the retinal pig-
ment epithelium, atrophy or neovascularization and irre-
versible severe visual loss [3]. The most common form
of late AMD is neovascular AMD (nAMD) which leads
to legal blindness within on average 2 years [4]. After
the introduction of vascular endothelial growth factor
inhibitors, the outcome has significantly improved for
these patients [5]. AMD currently affects more than 15
million individuals in the European Union (EU) alone
and more than 190 million globally [2, 6–9]. With popu-
lation aging, AMD prevalence is expected to increase
considerably over the next decades [2, 6].
Considering this background, novel treatment options
which prevent or slow down disease progression from
iAMD to late AMD and biomarkers that allow precise
identification of individuals at risk of progression are ur-
gently needed [10]. Currently, no validated clinical end-
points accepted by regulatory agencies, payers, and
health technology assessment (HTA) bodies are avail-
able. Best-corrected visual acuity (BCVA) at high con-
trast and high luminance is accepted as the only primary
study endpoint for neovascular AMD trials by author-
ities to date, but this marker does not detect the func-
tional deficit in early or iAMD sensitively [11, 12].
Individuals affected by iAMD frequently report difficul-
ties seeing in dim or changing light conditions as well as
in low-contrast surroundings [13, 14]. Visual function
tests designed to measure functional impairment under
these circumstances may be able to characterize the vis-
ual deficit in individuals with early and iAMD and might
allow for a more accurate prediction of the individual
risk of disease progression as well as be more patient-
relevant [15–17]. For these reasons, novel clinical end-
points for iAMD trials which are clinically meaningful
and acceptable to regulatory agencies need to be devel-
oped and validated. Besides single outcome measures,
combined parameters could function as candidate end-
points for future trials. The evaluation of different prom-
ising parameters not only from a functional point of
view but from a structural and a patient-reported stand-
point is a prerequisite to developing endpoints. Further-
more, the natural history of iAMD as well as risk factors
associated with disease progression to late AMD needs
to be better understood.
Overall, there is an urgent and unmet need for ad-
equate tools which would allow for interventional trials
to be conducted in early stages of AMD. The MACUS-
TAR study aims to fill this gap and develop and evaluate
functional, structural, and patient-reported candidate
endpoints for future use in iAMD trials.
Methods/design
The MACUSTAR clinical study consists of two parts and
combining a cross-sectional and a longitudinal component
to achieve the study objectives (see below). In the cross-
sectional part, four groups of participants with different
stages of disease (targets no AMD/normal aging changes,
n = 50; early AMD, n = 50; iAMD, n = 150; late AMD, n =
50) are planned to be included. The analysis of this part
incorporates two visits: the baseline visit at day 0 and a
short-term follow-up visit at day 14 (± 7 days). In the lon-
gitudinal part, a group of iAMD participants (target n =
600: n = 150 from the cross-sectional part, and n = 450
additional subjects) as well as the participants with early
AMD (target n = 50, recruited in the cross-sectional part)
are followed up for a 3-year period. The rationale of the
study and the justification for the sample size have been
described previously [18]. The MACUSTAR clinical study
is conducted, analyzed, and reported according to current
international laws and regulations and in compliance with
regulatory requirements in all participating countries and
the standards of good clinical practice according to the
International Council for Harmonisation of Technical Re-
quirements for Pharmaceuticals for Human Use. This
includes the submission of study protocol and any amend-
ments to the respective institutional review board/ethics
committee. This publication refers to protocol version 5.0
as approved on 15 July 2019. Future modifications will be
shared with the investigators, institutional ethics commit-
tees/review boards, and the scientific community as
indicated.
Study objectives
The main objective of the MACUSTAR study is to de-
velop novel clinical endpoints for future clinical trials with
a regulatory and patient access intention in patients with
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iAMD. Additional objectives are the characterization of
visual impairment in iAMD and its progression and the
identification of risk factors for progression to late AMD
(Table 1).
Study outcomes
The MACUSTAR study collects data in relation to func-
tional, structural, and patient-reported outcomes, includ-
ing best-corrected visual acuity, mean and point-wise
retinal sensitivities on scotopic/mesopic fundus-controlled
perimetry, low-luminance visual acuity (LLVA), low-
luminance deficit, Moorfields acuity chart visual acuity,
absolute threshold and rod intercept time of dark adapta-
tion, time to complete mobility course time, walking speed
and error rate, reading speed in words per minute and
number of words read correctly, central subfield retinal
thickness, total retinal volume, presence of refractile de-
posits, intraretinal cystoid spaces, choroidal neovasculari-
zation, maximum drusen size, presence of pigment
epithelium detachment, pigmentary abnormalities, reticu-
lar drusen, focal increased autofluorescence signal, vitelli-
form material, exsudation, geographic atrophy, and
patient-reported low-luminance functioning (Vision Im-
pairment in Low Luminance questionnaire). Besides this,
demographic data (year of birth, weight, height, gender,
race) and medical and ophthalmic history, concomitant
medications, adverse events, and prior non-ocular and
ocular treatments are documented. Information on the in-
clusion and exclusion and results of the physical examin-
ation (blood pressure, heart rate) and ophthalmologic
examination (external examination; screening for eyelid/
pupil responsiveness; slit-lamp examination of the cornea,
lens, and iris; indirect ophthalmoscopy; assessment of in-
traocular pressure; refraction; dilated fundus examination
of the optic nerve; peripheral retina and retinal vascula-
ture) are also recorded.
Design of the study
The MACUSTAR clinical study is a low-interventional
clinical multicenter study (i.e., no therapeutic intervention,
predefined set of subject assessments) to develop novel
candidate clinical endpoints for iAMD. The recruitment
period was planned to be 21months. The participants are
recruited at 20 clinical sites from seven European coun-
tries (Denmark, France, Germany, Italy, Netherlands,
Portugal, UK). The cross-sectional part (total duration, 1
month) and the longitudinal part (total duration, 36
months) plan to enroll 750 participants in total. Three
hundred individuals are planned be included in the cross-
sectional part (no AMD, n = 50; early AMD, n = 50; late
AMD, n = 50; iAMD, n = 150), and 650 participants are
planned to be included in the longitudinal part (iAMD,
n = 600; early AMD, n = 50). The study consists of three
phases: screening, inclusion, and follow-up phases.
Screening phase
The screening period (maximum duration, 4 weeks)
starts with the first study visit (V1). No treatment is
allowed during this phase except for late AMD subjects
and iAMD subjects included in the longitudinal part of
the study (unilateral iAMD). Participants are recruited at
the local level. Potential participants are recruited, e.g.,
at consultations and from pre-existing study participant
databases. The participants who sign the informed con-
sent form (ICF) perform the study procedures. The in-
vestigator must ensure that each subject is fully
informed about the nature and objective of the study
and possible risks associated with participation. Imaging
data obtained are transferred to the central reading cen-
ter (GRADE Reading Center, Bonn, Germany). Partici-
pants’ eligibility is evaluated by the local investigator
based on the inclusion and exclusion criteria (see below)
and on the disease stage of both eyes, as based on the
clinical classification of AMD according to the Beckman
classification [19]. Eligible participants are assigned to
one of the four groups included in the study: no AMD,
early AMD, iAMD, or late AMD. If both eyes are eligible
for the study based on inclusion criteria, the eye with
better visual acuity is selected as the study eye. In cases
in which both eyes have the same visual acuity, the study
Table 1 Objectives of the MACUSTAR study
Cross-sectional part Longitudinal part
Primary
objectives
Technical evaluation of functional and structural candidate
outcomes
Assessment of prognostic power of functional, structural, and
patient-reported outcomes for progression from iAMD to late AMD
Secondary
objectives
Correlation analyses between defined structural, functional,
and patient-reported outcome measures;
Evaluation of discriminative ability of outcome measures (with
respect to AMD stages and participants without AMD);
Implementation of a database for no AMD, early AMD, iAMD,
and late AMD
Correlation analyses between defined structural, functional, and
patient-reported outcome measures over time;
Evaluation of the natural history of iAMD biomarkers
Exploratory
objectives
Hypothesis-free testing of associations/correlations Identification of sub-stages of iAMD that relate to progression to late
AMD;
Assessment of the association of single and combined endpoints to
the final status of patients (progressed vs. not progressed);
Hypothesis-free testing of associations/correlations
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eye is selected by the investigator. Participants’ eligibility
with regard to the image-related inclusion/exclusion cri-
teria and slot availability for the respective group is fi-
nally confirmed by the central reading center within 48
h.
Inclusion and exclusion criteria
The following criteria determine eligibility for the
MACUSTAR study:
General inclusion criteria
1. Male and female participants.
2. Aged 55–85 years at baseline.
3. Able and willing to provide written informed
consent and to comply with the study protocol
visits and assessments. In case the individual is
physically incapable of signing the ICF, this can be
provided by a legally acceptable representative of
the participant or impartial witness.
Specific inclusion criteria for the iAMD group:
1. The study eye must have iAMD (defined by large
drusen > 125 μm and/or any AMD pigmentary
abnormalities that are definite hyper- or
hypopigmentary abnormalities associated with
medium or large drusen but not associated with
other known disease entities) and
2. Individuals to be included in the
a. Cross-sectional part: The fellow eye must have
iAMD and/or, in addition, extrafoveal
geographic atrophy (GA, no atrophy within the
central ETDRS subfield); maximum total GA
size is 1.25 mm2.
b. Longitudinal part: The fellow eye must have
AMD (early AMD, iAMD, or late AMD—any
stage of AMD is allowed).
3. Early Treatment Diabetic Retinopathy Study (ETDR
S) letter chart BCVA in the study eye not worse
than 72 letters (approximately 20/40 Snellen visual
acuity equivalent).
4. All general inclusion criteria.
Specific inclusion criteria for the late AMD group:
1. Individuals with bilateral GA, bilateral nAMD, or
nAMD in one eye and GA in the other.
 GA is defined as a retinal area at minimum size
of 0.1 mm2 that shows a severely decreased
fundus autofluorescence signal and correlates to
outer nuclear layer loss and an enhanced signal
of the choroid on spectral domain-optical coher-
ence tomography (SD-OCT). In addition, it
needs to be of limited size and show AMD
typical changes on color fundus photography
(CFP) such as depigmentation, hyperpigmenta-
tion, and crystalline deposits if hemorrhages or
exudates are absent.
 Choroidal neovascularization (CNV) is defined
based on CFP, SD-OCT, and/or fluorescein angi-
ography (FA, optional). At least two of the fol-
lowing signs must be present within a radius of
3000 μm of the fovea to confirm CNV: (1) serous
detachment of the sensory retina, (2) subretinal/
retinal hemorrhage, (3) pigment epithelial de-
tachment (excl. drusenoid pigment epithelial de-
tachment), (4) fibrous tissue, (5) hard exudates,
and (6) disciform scar. FA-confirmed CNV (with
corroborating evidence on OCT) is sufficient
without clinical signs of CNV.
2. BCVA between 20/80 and 20/200 in the study eye.
3. All general inclusion criteria.
Specific inclusion criteria for the early AMD group:
1. Individuals with medium drusen > 63 μm and ≤
125 μm and no AMD pigmentary abnormalities in
both eyes and no signs of intermediate or late
AMD.
2. All general inclusion criteria.
Specific inclusion criteria for the no AMD group:
1. No signs of early, intermediate, or late AMD in
both eyes.
2. All general inclusion criteria.
General exclusion criteria:
1. Media opacity or eye movement disorder
(nystagmus) that interferes with retinal imaging
data quality in the opinion of the investigator.
2. Severe ptosis, extraocular motility restriction, or
head tremor preventing adequate fundus
visualization in the opinion of the investigator.
3. Any signs of nAMD or GA (does not apply to the
late AMD group and to fellow eyes within the
intermediate AMD group for individuals to be
included in the longitudinal part only).
4. Any concurrent intraocular condition in the study
eye (e.g., glaucoma or cataract) that in the opinion
of the investigator would either require surgical
intervention during the study to prevent or treat
visual loss that might result from that condition or
affect interpretation of study results.
5. Severe non-proliferative diabetic retinopathy, or
proliferative diabetic retinopathy.
6. Any diabetic macular edema or macular disease.
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7. Ocular disorders in the study eye (i.e., pre-retinal
membrane) at the time of enrolment that may con-
found interpretation of study results and comprom-
ise visual acuity.
8. Diagnosis of uncontrolled glaucoma with
intraocular pressure of > 30 mmHg (despite current
pharmacological or non-pharmacological
treatment).
9. Known systemic illness which in the opinion of the
investigator will prevent from actively participating
in the study.
10. Concomitant treatment for AMD in either eye
(concomitant use of vitamins/supplements is not
excluded; does not apply to the late AMD group
and to fellow eyes within the intermediate AMD
group for individuals to be included in the
longitudinal part only).
11. Any periocular or intravitreal injections (IVT) in
either eye (does not apply to the late AMD group
and to fellow eyes within the intermediate AMD
group for individuals to be included in the
longitudinal part only).
12. Participation in any other interventional trial.
13. Obvious retinal changes due to causes other than
AMD (e.g., evidenced by an existing diagnosis of
monogenetic macular dystrophies, Stargardt disease,
cone rod dystrophy, or toxic maculopathies).
14. Any history of allergies to fluorescein.
15. Cognitive impaired individuals, illiterate, and
individuals who do not speak the national language.
Specific exclusion criteria for the iAMD group:
1. Any GA in the study eye.
2. Any extrafoveal GA larger than 1.25 mm2 (as
defined above) in the fellow eye (only applies to
individuals to be included in the cross-sectional
part).
3. All general exclusion criteria.
Specific exclusion criteria for the late AMD group:
1. All general exclusion criteria only.
Specific exclusion criteria for the early AMD group:
1. Intermediate or late AMD (following Beckman
classification) in any eye.
2. All general exclusion criteria.
Specific exclusion criteria for the no AMD group:
1. Early to late AMD (following Beckman
classification) in any eye.
2. All general exclusion criteria.
Inclusion phase
The inclusion phase contains the baseline visit (V2). If
an individual is eligible after screening and participant
slots are available for the respective group, V2 is sched-
uled within 30 days from the screening visit (V1). At the
baseline visit, the clinical site confirms the inclusion/ex-
clusion criteria to ensure that the individual remains eli-
gible. Participants are informed about the planned
number of follow-up visits and the duration of their par-
ticipation in the study (Table 2).
Follow-up phase
The follow-up phase comprises visit 3 (day 14) to visit 9
(month 36). Patients who progress from early or iAMD
to late AMD during follow-up remain in the study for
the whole follow-up period and are examined according
to the Clinical Study Protocol. The respective patients
can be treated according to the standard of care if
deemed necessary by the treating physician. If a partici-
pant prematurely terminates the study, the investigator
should attempt to complete the assessments of visit 9
(discharge visit). These data are planned to be included
in the analysis unless consent is withdrawn.
Unscheduled visits may be necessary during the study
as part of the assessment of adverse events or other
safety concerns. The investigator should consider per-
forming only the necessary study procedures, on a case-
by-case basis. The acquired imaging data, if any, should
be transferred to the central reading center, and an un-
scheduled visit must be completed on the electronic case
report form (eCRF).
Study procedures
The assessments have been structured in a way that al-
lows the study participants to perform less and more de-
manding tests in an order that reduces signs of fatigue
for the participants and allows the examiner to obtain
the data in an efficient way. Examinations requiring
pupil dilation are performed in the second part of the
study visit since mainly the chart-based functional tests
have to be administered to patients prior to pupil dila-
tion. In the screening visit, obtaining consent from the
participant is the mandatory first step prior to any study
examinations. The individual clinical sites are allowed to
adapt the following visit schedule recommendation de-
veloped for MACUSTAR to the local settings. Staff
training and, for some procedures, certification are re-
quired before data are acquired.
Blood collection and chart-based function tests (refrac-
tion and best-corrected visual acuity according to the
ETDRS protocol, in sitting position at an initial testing
distance of 4 m, Moorfields acuity test, low-luminance
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visual acuity, contrast sensitivity) are recommended to
precede the assessment of reading speed. For sites
equipped for navigational testing, the respective course
is performed on a separate visit within 21 days. The
interview-based administration of the VILL and EQ5D-
5 L questionnaires can be performed after application of
dilating eye drops for the following examinations. Fun-
dus imaging including OCT, CFP, and scanning laser
ophthalmoscopy (see study schedule, Table 3) are rec-
ommended to be performed next, followed by two ex-
aminations that require prior dark adaptation (5 min for
mesopic fundus-controlled perimetry [also called micro-
perimetry], additional 30 min for scotopic testing). De-
tails on these examinations performed have been
described previously [18]. All images are acquired by
certified staff and evaluated centrally by trained
personnel at the central reading center. Staff certifica-
tions are based on respective standard operating proce-
dures and contain the upload of images and/or passing a
written examination on the respective procedures.
Lastly, the ophthalmological examination may complete
the study visit. The overall duration of a MACUSTAR
visit was tested to be about 4 h which participants re-
ported to be acceptable.
Study completion
Participants have achieved study completion if the
following visits are completed successfully: V3 for in-
dividuals participating in the cross-sectional part only
(participants with no AMD and late AMD) and V9
for subjects participating in the longitudinal part (par-
ticipants with iAMD and early AMD). The end of the
clinical study corresponds to the last visit of the last
participant. The study can be prematurely terminated
at any time by the sponsor for any sufficient reason.
Overall, patients with iAMD are at risk of progression
to late AMD. Providing state-of-the-art high-
resolution retinal imaging and monitoring progres-
sion, which are thus potentially picked up early, will
create a large incentive for the patients to remain in
the study. We will also provide a capped travel reim-
bursement if requested by the patient.
Safety assessments
The MACUSTAR study is a low-interventional study,
and it does not investigate any therapeutic interventions.
All devices used are already marketed in the study coun-
tries or are market-ready. As almost all assessments and
procedures (except for FA and blood collection) are
non-invasive, most adverse events may be due to the
natural progression of the underlying disease or occur-
rence of concomitant diseases. All adverse events (de-
fined as any unfavorable and unintended sign, symptom
or disease temporally associated with the use of any
study procedure, whether or not considered related to
the study procedure) and serious adverse events (defined
as any untoward medical occurrence or effect that re-
sults in death, is life threatening, requires hospitalization
or prolongation of existing hospitalization, results in per-
sistent or significant disability or incapacity, is a con-
genital anomaly or birth defect or is an important
medical event) are collected in the eCRF. The serious
adverse events are reported in a serious adverse event
report form. The conversion to late AMD does not fulfill
the criteria of a serious adverse event according to the
study criteria.
Data management and quality assurance
All clinical data are entered by the investigators or desig-
nated staff into the eCRF. Clinical staff is given access to
eCRF after training on a platform in advance. Imaging
data will be exchanged between clinical sites and the
central reading center through an internet portal and
stored on a secure server. All data are stored in pseudo-
nymized form.
Monitoring happens throughout the study with clinical
monitors from the European clinical research infrastruc-
ture network visiting the clinical site for site initiation
visit followed by regular 6 monthly visits throughout the
study to ensure compliance with the study protocol as
well as regulatory requirements and good clinical prac-
tice (according to the International Council for Harmon-
isation of Technical Requirements for Pharmaceuticals
for Human Use). Monitors and the data management
team review the eCRF for completeness and accuracy
and instruct clinical site personnel to make any required
Table 2 Visits to be performed according to the AMD group
Study phase Screening Baseline Follow-up
Visit number 1 2 3 4 5 6 7 8 9
Visit day/month − 28D 0 14D 6M 12M 18M 24M 30M 36M
No AMD X X X
Early AMD X X X X X X
Late AMD X X X
Intermediate AMD X X X* X X X X X X
*This visit is only performed by subjects included on the cross-sectional part
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corrections or additions. During monitoring visits, moni-
tors will ensure that the data included in the eCRF is
supported by data in the source documents. Queries are
sent to the clinical site as applicable. Designated clinical
site staff is required to respond to the queries and make
the necessary changes to the data. Data management is
performed using automatic data validation requests
within the eCRF, supplementary periodic validation
checks performed by the data management team. Miss-
ing data detected and queries raised on this basis are
Table 3 Study schedule of MACUSTAR
Study phase Screening Baseline Follow-up
Visit number 1 2 3* 4 5 6 7 8 9
Visit day/month − 28D 0 14D 6M 12M 18 M 24M 30M 36M
Allowed window Up to 4-week interval ± 7D ± 1M ± 1M ± 1M ± 1M ± 1M ± 1M
Procedures
Informed consent (clinical study) X
Informed consent (genetics/biosamples) X
History (medical + ocular) X
Inclusion/exclusion criteria X (X)1
Demographics X
Consultation with physician X X X X X X X X X
VILL questionnaire X X X X X X X X
EQ-5D-5L questionnaire X X X X
Funduscopy OU OU OU OU OU OU OU OU OU
Slit-lamp examination OU OU OU OU OU OU OU OU OU
Intraocular pressure OU OU OU OU OU OU OU OU OU
Refraction OU OU OU OU OU OU OU OU
BCVA OU OU OU OU OU OU OU OU OU
LLVA OU OU OU OU OU OU OU OU
Moorfields Acuity Test (MAT) OU OU OU OU OU OU OU OU
Contrast sensitivity (Pelli Robson) OU OU OU OU OU OU OU OU
Reading test (International Reading Speed Texts)3 X X X X X X X X
Fundus-controlled perimetry (scotopic + mesopic)7 SE SE SE SE SE SE SE SE
Absolute threshold (dark adaptation)7 SE SE SE SE SE SE SE SE
Spectralis imaging (cSLO, fundus autofluorescence, SD-OCT)7 OU OU SE SE OU SE SE OU
Cirrus OCT imaging7 OU OU SE SE OU SE SE OU
Color fundus photography7 OU OU SE SE OU SE SE OU
Fluorescein angiography2,7 (OU) (OU) (OU) (OU) (OU) (OU) (OU) (OU) (OU)
OCT-angiography3,7 OU SE SE SE OU SE SE OU
Swept-source OCT3,7 OU SE SE SE OU SE SE OU
Adaptive optics imaging3 OU SE SE SE OU SE SE OU
Quantitative fundus autofluorescence3,7 OU SE SE SE OU SE SE OU
Additional assessments
Navigation performance4 X
Blood sampling—Biobanking5 X X X X
Blood sampling—genetics X6
Concomitant medications X X X X X X X
Adverse events X X X X X X X X
D days, M Months, OU both eyes (eyes are tested separately), SE study eye. *This visit is only performed by subjects on the cross-sectional part. 1Check for
eligibility based on CRC assessment. 2To be done at the study site when there is suspicion of conversion to CNV. 3At equipped sites only. 4At selected sites only.
5Plasma, serum, and DNA are biobanked for future analyses. 6Blood collection for Genetics should occur at baseline visit, but it can occur at any time during the
subject follow-up. 7Images to be sent to the central reading center
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regularly communicated to the clinical sites and the
monitors. Finally, manual data validation checks are im-
plemented by the data management team as needed.
Missing values are regularly analyzed during the
course of the study. Missing values are replaced using
multiple imputation with 10 imputed data sets wherever
possible. Variables with more than one third missing
values in any of the visits will be checked for visit-wise
exclusion from statistical analysis. If a variable contains
less than or equal to 3% missing values per visit, these
missing values will be imputed using univariate mean,
median, or mode imputation. Complete-case analyses
will be carried out in order to investigate the sensitivity
of results with regard to multiple imputation
procedures.
Dissemination of results
Upon study completion and final study report, the re-
sults of this study will be submitted for publication in
order to share the achieved scientific results with peers
at local and international journals/congresses. Author-
ship rules follow the guidelines of the international com-
mittee of medical journal editors. The MACUSTAR data
access and publication committees coordinate these ef-
forts. Relevant results will be shared with patient organi-
zations and the general public in press releases.
Regulator interaction
A joint scientific advice procedure with the European
Medicines Agency (EMA), Food and Drug Administra-
tion (FDA), and Health Technology Assessment (HTA)
bodies (in this case NICE, UK) on the proposed
MACUSTAR clinical study design and selected outcome
measures was initiated by the MACUSTAR consortium
in 2016 prior to study start. The regulators supported
the approach of the study to develop and validate func-
tional and structural clinical endpoints with patient-
reported outcome measures as secondary endpoints for
future clinical trials on iAMD. Also, they advised to
share relevant study results supporting endpoint valid-
ation with all regulatory bodies. Following this, EMA
published a letter of support for the MACUSTAR clin-
ical study (available at www.ema.europa.eu). Further sci-
entific advice procedures are planned once clinical study
data become available.
Discussion
Considering the expected increase in affected individuals
with AMD due to population aging as well as the con-
siderable adverse impact of AMD on the affected person,
their families, and society at large, we need to urgently
pave the way for the development of interventions to
prevent, stop, or delay the disease in its early stages. The
MACUSTAR study will deliver necessary tools to
conduct these much needed clinical trials and enable fu-
ture development of early and iAMD interventions. An
ongoing dialogue with regulators will ensure that regula-
tor expectations and feedback are met and increase the
likelihood of developed outcomes being accepted as clin-
ical endpoints by regulators.
Multiple functional tests included in the MACUSTAR
study will be able to comprehensively characterize the
functional deficit of AMD patients, mainly present at
low light levels and in low contrast situations [15, 20,
21]. The functional testing will be complemented by in-
novative multimodal imaging modalities and patient-
reported outcome measures optimized for the specific
functional impairment in early AMD stages. Out of the
functional testing employed, fundus-controlled perim-
etry [22, 23] is a promising functional candidate end-
point in iAMD as it could characterize the localized
functional deficit in AMD well in previous studies [11,
13, 24–28]. The MACUSTAR study implements its
mesopic and scotopic variants to simulate conditions
under which persons with early and iAMD are expected
to experience functional deficits. For example, visual im-
pairment after dark adaptation has been shown to be re-
lated to retinal structural changes in individuals with
iAMD [25]. Other functional candidate endpoints in-
clude dark adaptometry and chart-based tests. An im-
paired process of dark adaptation in healthy individuals
predicted AMD onset over 3 years [29], and there is evi-
dence of its association with disease progression [30].
Chart-based tests are easy and rapid to administer and
have shown associations with AMD progression [31–33].
For this purpose, different types including low-
luminance visual acuity and contrast sensitivity are used
as candidate functional endpoints in the MACUSTAR
study. However, no long-term data in large cohorts exist
for these functional parameters as of yet.
Different to functional outcome measure, structural out-
come measures allow for a participant-independent, ob-
jective assessment of disease stage and progression. AMD
is characterized by a number of retinal biomarkers which
are captured in MACUSTAR using high-resolution, non-
invasive retinal imaging. These current imaging modalities
are known to be more sensitive in the detection of ad-
vanced AMD and allow for the evaluation of a wider var-
iety of structural endpoints [34–36]. Implementing state-
of-the-art, multimodal retinal imaging technologies, large
volumes of data are created. Automated and semi-
automated quantification of imaging biomarkers have
shown promising results in the detection and quantifica-
tion of retinal AMD biomarkers [37–39]. In the MACUS-
TAR study, we are able to compare such new approaches
to the current gold standard of manual grading by a cen-
tral reading center as well as assess combined structural
and functional outcome measures.
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Endpoints combining functional and structural data
have become increasingly relevant for studies of slowly
progressing diseases such as AMD or glaucoma. In glau-
coma clinical research, not only the slow progression of
the disease but also the considerable noise in perimetry-
based functional endpoints historically necessitated very
large sample sizes [40]. Adding a structural dimension to
a functional endpoint has shown to improve predictive
accuracy for short-term data, increase the statistical
power of tests, and therefore allow for reduced sample
sizes in clinical trials [41, 42]. We will explore combined
functional and structural endpoints in iAMD following
this prescription from glaucoma clinical research.
Patient-reported outcomes (PRO) are increasingly im-
portant in clinical research. As many of the available
vision-related PRO instruments either do not capture
the specific visual impairment in early AMD stages or
have not been developed with regulatory requirements
in mind, we use a newly and specifically developed PRO,
the Vision Impairment in Low Luminance (VILL) ques-
tionnaire in the MACUSTAR study. The PRO will aid in
determining patient relevance of changes in structure
and function.
Surrogate endpoints are required in many slowly pro-
gressive diseases or when events of interest occur rarely
or are difficult to capture [43]. They have been widely
used in clinical trials in ophthalmology with, for in-
stance, intraocular pressure being one of the most com-
mon endpoints in glaucoma trials [44, 45]. In AMD
clinical trials, only high-luminance, high-contrast best-
corrected visual acuity has been available as a regulator
accepted primary efficacy outcome measure for the ap-
proval of new therapeutics in ophthalmology [45], an
outcome measure inapplicable to earlier AMD stages.
Following the 2016 Endpoints Workshop on Age-
Related Macular Degeneration and Inherited Retinal
Diseases organized by the National Eye Institute (NEI,
National Institute of Health, USA) and the United States
Food and Drug Administration (FDA), it was noted that
structural candidate endpoints require evident strong
correlations with functional biomarkers in order to be-
come accepted trial endpoints [12]. Patient-reported
outcomes were proposed as meaningful secondary out-
come measures for future trials in AMD by regulatory
agencies and therefore should also be considered [45].
Despite available data on functional, structural, and
patient-reported outcome measures in iAMD, surrogate
biomarkers require careful validation to avoid potential
harm as seen by regulators [46, 47]. According to the
well-established Prentice criteria, the effect of a treat-
ment is always mediated by true surrogate endpoints,
which is a unidirectional process. The hard outcome
measure must not be affected by the treatment in any
parallel way [48, 49]. Applied to the development of
clinical trial endpoints in AMD, candidate endpoints
need to be understood profoundly in both a longitudinal
and a cross-sectional setting, which will be provided in
the MACUSTAR study.
With more than 190 million people currently affected
by AMD globally [9], there is an urgent, yet unmet need
for interventions to prevent, stop, or delay AMD and its
progression. For this, however, we need to be able to
conduct efficient clinical trials with appropriate clinical
endpoints accepted by regulators. Considering this back-
ground, the MACUSTAR study will develop appropriate
outcome measures and engage with regulators to estab-
lish clinical trial endpoints for future clinical trials in
iAMD to fill this gap.
Trial status
Current protocol version: 5.0 (15 July 2019); currently
recruiting (since 01 March 2018).
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